Early experience of Sacubitril –Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting

ConclusionsAmong HFrEF patients in this real ‐world cohort, 20% were eligible for ARNI; however, only 13% received the treatment. Sac/Val was well tolerated, but 41% of the patients did not reach target dose. How this affects outcome is not known and needs further investigation.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research